Amylyx Pharmaceuticals Inc

AMLXNASDAQ · USD
30.29USD0.00 (+1.44%)
2210

Amylyx Pharmaceuticals Inc (AMLX) Covered Calls

Amylyx Pharmaceuticals Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 34.92%, average versus the past year. AMLX's highest covered call setup is the $34.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 12.25% out of the money with 35 days to expiration, a 14.39% return until expiration, and a 150.11% theoretical annualized return. Across the setups shown, annualized returns run from 77.81% to 150.11% at strikes between $32.00 and $45.00, with 35 to 189 days to expiration, as of Nov 13, 2026.

Read more

Running AMLX covered calls helps you generate income from Amylyx Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AMLX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AMLX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AMLX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AMLX covered call is worth writing.

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

2026-12-183534.0012.250.651.70436.0014.39150.11-2.15+0.3351.05
2026-12-183533.008.950.801.20351.0011.59120.85-2.64+0.341920.40
2027-01-156336.0018.850.053.80576.0019.02110.17-0.17+0.3553.75
2027-01-156335.0015.550.701.85541.0017.86103.48-2.31+0.322621.15
2027-05-2118945.0048.560.402.951511.0049.8896.34-1.32+0.2612.55
2027-02-199837.0022.150.252.35696.0022.9885.58-0.83+0.2912.10
2027-03-1912639.0028.760.152.35886.0029.2584.73-0.50+0.2602.20
2027-01-156334.0012.250.552.20426.0014.0681.48-1.82+0.3501.65
2027-03-1912638.0025.450.452.50816.0026.9478.04-1.49+0.2902.05
2026-12-183532.005.650.552.20226.007.4677.81-1.82+0.4141.65

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank34.92% Moderate
  • Market cap (M$)3,894
  • 52 weeks high-26.37%
  • 52 weeks low179.69%
  • Analyst recommendationStrong Buy
    1.25
  • Target price$43.00
    41.96% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.45
  • EPS growth next 5 years31.01%

As of Nov 13, 2026